Cyclooxygenase inhibition and rosuvastatin-induced vascular protection in the setting of ischemia-reperfusion: A human in vivo study

Vascular Pharmacology

Volumn 71, Issue , 2015, Pages 159-165

  Kwong, Wilson ^a,b   Liuni, Andrew ^a,b   Zhou, Kangbin ^a,b   Parker, John D ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cyclooxygenase inhibition; Endothelial dysfunction; Flow mediated dilation; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; IBUPROFEN; PLACEBO; PROSTAGLANDIN SYNTHASE; ROSUVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ARTERY DIAMETER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FOREARM; HUMAN; IN VIVO STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RADIAL ARTERY; REPERFUSION INJURY; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; UPREGULATION; ADOLESCENT; BLOOD FLOW VELOCITY; BLOOD PRESSURE; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEART RATE; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HEART RATE; HUMANS; MALE; REPERFUSION INJURY; ROSUVASTATIN CALCIUM; SINGLE-BLIND METHOD; VASODILATION; YOUNG ADULT;

EID: 84937977304     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.03.010     Document Type: Article

References (54)

1. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
2. Lange S.A., Wolf B., Schober K., Wunderlich C., Marquetant R., Weinbrenner C., et al. Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart. J Cardiovasc Pharmacol 2007, 49:46-55.
3. Gori T., Di Stolfo G., Sicuro S., Dragoni S., Lisi M., Forconi S., et al. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol 2007, 64:145-150.
4. Gori T., Sicuro S., Dragoni S., Donati G., Forconi S., Parker J.D. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005, 111:742-746.
5. Atar S., Ye Y., Lin Y., Freeberg S.Y., Nishi S.P., Rosanio S., et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 2006, 290:H1960-H1968.
6. Zhu B., Sun Y., Sievers R.E., Browne A.E., Pulukurthy S., Sudhir K., et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol 2000, 35:787-795.
7. Ferdinandy P., Hausenloy D.J., Heusch G., Baxter G.F., Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014, 66:1142-1174.
8. Ferdinandy P., Schulz R., Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007, 59:418-458.
9. Laufs U., Gertz K., Dirnagl U., Bohm M., Nickenig G., Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002, 942:23-30.
10. Hausenloy D.J., Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004, 61:448-460.
11. Bolli R., Shinmura K., Tang X.L., Kodani E., Xuan Y.T., Guo Y., et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002, 55:506-519.
12. Liuni A., Luca M.C., Gori T., Parker J.D. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010, 55:1002-1006.
13. Birnbaum Y., Ye Y., Rosanio S., Tavackoli S., Hu Z.Y., Schwarz E.R., et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005, 65:345-355.
14. Kocsis G.F., Pipis J., Fekete V., Kovacs-Simon A., Odendaal L., Molnar E., et al. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 2008, 294:H2406-H2409.
15. Fan Y., Yang S., Zhang X., Cao Y., Huang Y. Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats. Clin Exp Pharmacol Physiol 2012, 39:938-943.
16. Liuni A., Luca M.C., Gori T., Parker J.D. Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study. Am J Physiol Heart Circ Physiol 2012, 302:H153-H158.
17. Dragoni S., Di Stolfo G., Sicuro S., Lisi M., Parker J.D., Forconi S., et al. Postconditioning fails to prevent radial artery endothelial dysfunction induced by ischemia and reperfusion: evidence from a human in vivo study. Can J Physiol Pharmacol 2006, 84:611-615.
18. Mensah K., Mocanu M.M., Yellon D.M. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?. J Am Coll Cardiol 2005, 45:1287-1291.
19. Schulz R. Pleiotropic effects of statins: acutely good, but chronically bad?. J Am Coll Cardiol 2005, 45:1292-1294.
20. Shinmura K., Kodani E., Xuan Y.T., Dawn B., Tang X.L., Bolli R. Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J Am Coll Cardiol 2003, 41:1183-1194.
21. Birnbaum Y., Lin Y., Ye Y., Martinez J.D., Huang M.H., Lui C.Y., et al. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol 2007, 292:H2891-H2897.
22. Gross E.R., Hsu A.K., Gross G.J. Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. J Pharmacol Exp Ther 2004, 310:185-191.
23. Xu X.M., Sansores-Garcia L., Chen X.M., Matijevic-Aleksic N., Du M., Wu K.K. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A 1999, 96:5292-5297.
24. Dupouy V.M., Ferre P.J., Uro-Coste E., Lefebvre H.P. Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. J Appl Physiol 2006, 100:233-239.
25. Caughey G.E., Cleland L.G., Gamble J.R., James M.J. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem 2001, 276:37839-37845.
26. Jiang H., Weyrich A.S., Zimmerman G.A., McIntyre T.M. Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E2 production that modulate motility. J Biol Chem 2004, 279:55905-55913.
27. Smith L.H., Petrie M.S., Morrow J.D., Oates J.A., Vaughan D.E. The sterol response element binding protein regulates cyclooxygenase-2 gene expression in endothelial cells. J Lipid Res 2005, 46:862-871.
28. Liesmaa I., Kokkonen J.O., Kovanen P.T., Lindstedt K.A. Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells. J Mol Cell Cardiol 2007, 43:593-600.
29. Cryer B., Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104:413-421.
30. Jugdutt B.I., Hutchins G.M., Bulkley B.H., Becker L.C. Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog. Am J Cardiol 1980, 46:74-82.
31. Antman E.M., DeMets D., Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005, 112:759-770.
32. Bouchard J.F., Chouinard J., Lamontagne D. Participation of prostaglandin E2 in the endothelial protective effect of ischaemic preconditioning in isolated rat heart. Cardiovasc Res 2000, 45:418-427.
33. Camitta M.G., Gabel S.A., Chulada P., Bradbury J.A., Langenbach R., Zeldin D.C., et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 2001, 104:2453-2458.
34. Gres P., Schulz R., Jansen J., Umschlag C., Heusch G. Involvement of endogenous prostaglandins in ischemic preconditioning in pigs. Cardiovasc Res 2002, 55:626-632.
35. Moench I., Prentice H., Rickaway Z., Weissbach H. Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms. Proc Natl Acad Sci U S A 2009, 106:19611-19616.
36. Bhattacharya P., Pandey A.K., Paul S., Patnaik R. Neuroprotective potential of piroxicam in cerebral ischemia: an in silico evaluation of the hypothesis to explore its therapeutic efficacy by inhibition of aquaporin-4 and acid sensing ion channel1a. Med Hypotheses 2012, 79:352-357.
37. Smith S.C., Benjamin E.J., Bonow R.O., Braun L.T., Creager M.A., Franklin B.A., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011, 58:2432-2446.
38. Peters R.J., Mehta S.R., Fox K.A., Zhao F., Lewis B.S., Kopecky S.L., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003, 108:1682-1687.
39. Yu J., Mehran R., Dangas G.D., Claessen B.E., Baber U., Xu K., et al. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 2012, 5:1231-1238.
40. Mahaffey K.W., Wojdyla D.M., Carroll K., Becker R.C., Storey R.F., Angiolillo D.J., et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011, 124:544-554.
41. Gislason G.H., Jacobsen S., Rasmussen J.N., Rasmussen S., Buch P., Friberg J., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006, 113:2906-2913.
42. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-1644.
43. Kohli P., Steg P.G., Cannon C.P., Smith S.C., Eagle K.A., Ohman E.M., et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med 2014, 127:53-60. [e1].
44. Olsen A.M., Fosbol E.L., Lindhardsen J., Andersson C., Folke F., Nielsen M.B., et al. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients-a nationwide study. PLoS One 2013, 8. [e54309].
45. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954-959.
46. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091.
47. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Bertagnolli M and Adenoma Prevention with Celecoxib Study I. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
48. McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011, 8. [e1001098].
49. Farkouh M.E., Greenberg J.D., Jeger R.V., Ramanathan K., Verheugt F.W., Chesebro J.H., et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007, 66:764-770.
50. Farkouh M.E., Verheugt F.W., Ruland S., Kirshner H., Jeger R., Gitton X., et al. A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen. J Clin Hypertens (Greenwich) 2008, 10:592-602.
51. Aljadhey H., Tu W., Hansen R.A., Blalock S.J., Brater D.C., Murray M.D. Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord 2012, 12:93.
52. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
53. Li Y., Jiang X., Lan K., Jiang Q. Comparative single- and multiple-dose pharmacokinetics of rosuvastatin following oral administration in Chinese volunteers. Eur J Drug Metab Pharmacokinet 2009, 34:221-227.
54. Martin P.D., Warwick M.J., Dane A.L., Brindley C., Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003, 25:2553-2563.